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The C-type lectin domain (CTLD) group 14 family of transmembrane gly-
coproteins consist of thrombomodulin, CD93, CLEC14A and CD248 (en-
dosialin or tumour endothelial marker-1). These cell surface proteins
exhibit similar ectodomain architecture and yet mediate a diverse range of
cellular functions, including but not restricted to angiogenesis, inflamma-
tion and cell adhesion. Thrombomodulin, CD93 and CLEC14A can be
expressed by endothelial cells, whereas CD248 is expressed by vasculature
associated pericytes, activated fibroblasts and tumour cells among other
cell types. In this article, we review the current literature of these family
members including their expression profiles, interacting partners, as well as
established and speculated functions. We focus primarily on their roles in
the vasculature and inflammation as well as their contributions to tumour
immunology. The CTLD group 14 family shares several characteristic fea-
tures including their ability to be proteolytically cleaved and engagement
of some shared extracellular matrix ligands. Each family member has
strong links to tumour development and in particular CD93, CLEC14A
and CD248 have been proposed as attractive candidate targets for cancer
therapy.
Introduction: C-type lectin domain group 14 family
There are 17 families in the C-type lectin domain
(CTLD) containing superfamily described in
humans. This superfamily comprises a range of
remarkably diverse proteins that can be secreted or
expressed on the cell surface. They mediate a wide
range of functions including but not limited to
Abbreviations
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ECD, extracellular domain; EGF, epidermal growth factor; EGFR1, epidermal growth factor receptor-1; EMT, epithelial mesenchymal
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inflammation, cell adhesion and carbohydrate recog-
nition [1].
Thrombomodulin, CD248, CD93 and CLEC14A
represent members of the CTLD group 14 family
which share common domain architecture (Fig. 1).
Each member is comprised of an N-terminal signal
peptide and a CTLD containing eight conserved cys-
teine residues. This is followed by a sushi-like or com-
plement control protein domain (also commonly
referred to as a short consensus repeat), except for
thrombomodulin which due to a lack of four con-
served cysteine residues in this region does not satisfy
the requirement for a sushi domain. Next are a num-
ber of EGF-like domain repeats, thrombomodulin
contains six, CD93 five, CD248 three and CLEC14A
one. These are followed by a mucin-like region of vari-
able length which is proline, serine and threonine rich
and encompasses many predicted O-linked glycosyla-
tion sites. Finally, there is a single-pass transmembrane
region that connects to a cytoplasmic tail.
The CTLD was originally described as a calcium
(Ca2+)-dependent carbohydrate binding domain,
although not all CTLDs require Ca2+ or demonstrate
carbohydrate binding activity. The overall CTLD-fold
is characterised by a so called ‘loop in a loop’ structure
stabilised by a conserved set of residues which con-
tribute to a distinctive hydrophobic core [1]. CTLD
containing proteins have been widely described in many
species and can even be found in the Bordetella bron-
chiseptica bacteriophage [2]. Sushi domains exhibit
extensive sequence variation but are generally charac-
terised by four conserved cysteines (forming two disul-
fide linkages in a 1–4 and 2–3 pattern) and an invariant
tryptophan, which contribute to preserving its tertiary
structure [3]. The sushi domain is an extracellular motif
that can contribute to protein–protein interactions, best
exemplified in interleukin-15 receptor-a (IL-15Ra)
recognition of IL-15 [4]. EGF-like domains are evolu-
tionary conserved modules, which derive their name
from the epidermal growth factor where they were orig-
inally described. EGF-like domains are found in a wide
range of proteins, chiefly of animal origin and are fre-
quently observed in tandem repeats. Each EGF module
typically consists of 30–40 amino acids and includes six
conserved cysteines which form three intramolecular
disulfide bonds [5]. The highly glycosylated mucin
region is commonly associated with adhesion proteins
as described for CD164 [6] and offers protection
against protein degradation by preventing access to
proteases. In addition, the presence of many O-linked
sugar moieties most likely allows proteins to adopt a
more rigid and extended conformation [7]. All of the
CTLD group 14 family members have been detected at
a much higher molecular weight than one would expect
based on their primary amino acid sequences. These
apparent disparities can be attributed to high degrees
of post-translational modifications, most likely glycosy-
lation. Consistent with this hypothesis, when CD248 is
treated with O-glycanase and sialase, its molecular
weight is reduced from 165 to 95 kDa when purified
from human neuroblastoma cells [8]. Similar findings
have been reported when CD93 is treated with enzymes
that remove O-glycosylation [9]. It is interesting to note
that electron microscopy analysis of thrombomodulin
revealed an elongated molecule with a large globular
nodule at one end and a smaller nodule at the other
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Fig. 1. CTLD group 14 family proteins.
Schematic diagrams of the CTLD group 14
family proteins. Each protein is drawn to
relative scale based on primary amino acid
sequence length. The CTLD is shown in
red, the sushi in blue and the EGF repeats
in green.
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[10]. If we assume that the larger nodule is likely the
CTLD, the smaller one is most likely comprised of the
EGF repeats. Since the overall domain architecture of
CTLD group 14 family members is relatively con-
served, it is tempting to speculate that they all display a
similar elongated structure with the membrane-distal
CTLD interacting with its cognate ligands. Addition-
ally, the domain layout of CTLD, sushi and EGF mod-
ules are reminiscent of the CTLD group 4 selectin
family of cell adhesion molecules, albeit in a different
order [11]. Similar to the group 4 family, there are
numerous examples of the CTLD group 14 family
mediating roles in adhesion (see below).
Based on whole protein sequence alignment, the
family member with closest homology to CLEC14A is
CD248 and CD93 is most closely related to thrombo-
modulin (Fig. 2). It has been suggested that CD93
could have arisen from thrombomodulin by gene
duplication events as each is present on chromosome
20 in humans [12].
Thrombomodulin
Thrombomodulin (THBD or CD141) is the most
extensively studied member of the CTLD group 14
family and is expressed by endothelium of all blood
vessels and lymphatics [12,13]. It is also localised on a
range of other cell types including but not restricted to
monocytes, neutrophils and dendritic cells [14].
Thrombomodulin is expressed early in development
and mice lacking the gene show embryonic lethality
[15]. Interestingly, thrombomodulin-deficient mouse
embryos die at embryonic day 8.5 due to defects in
nonendothelial tissue within the placenta, but reintro-
duction of thrombomodulin into the placenta allows
normal development of embryos until day 12.5 [16].
This suggests two distinct roles for thrombomodulin
during development, one in the placenta and the other
in the embryo. Nevertheless, thrombomodulin is the
only family member that following genetic deletion
causes embryonic lethality, suggesting that it exhibits
an indispensable role. This lethal phenotype is not
dependent on the CTLD or the cytoplasmic tail, as
mice that lack these modules remain viable [17,18].
Based on these considerations, such embryonic lethal-
ity is most likely due to disruptions in the thrombo-
modulin-mediated coagulation cascade elicited by the
EGF domain tandem repeats (see below).
Thrombomodulin and coagulation
One of the major roles for thrombomodulin is regulat-
ing the coagulation cascade by binding to the serine
protease thrombin [19]. The mode of recognition for
this physiologically relevant co-factor involves the
EGF modules of thrombomodulin as determined by
the crystal structure of the thrombomodulin–thrombin
complex [20]. This binding event inhibits procoagulant
thrombin-mediated hydrolysis of fibrinogen to fibrin,
thereby inducing an anticoagulative effect [21]. Throm-
bomodulin–thrombin binding also increases by
approximately 1000-fold the thrombin-mediated cleav-
age and activation of the anticoagulant serine protease
protein C [19]. Activated protein C is involved in the
inactivation of procoagulant factors FVa and FVIIIa
[19,22]. In addition, thrombomodulin–thrombin com-
plexes enhanced by approximately 1250-fold the acti-
vation of the antifibrinolytic TAFI (thrombin
activatable fibrinolysis inhibitor) [23]. Therefore, by
redirecting its cleavage activity towards the activation
of anticoagulant and antifibrinolytic proteins, throm-
bomodulin can dampen the coagulation cascade by
different mechanisms. Recently, the regulators of
angiogenesis angiopoietin-1 (Ang-1) and angiopoietin-
2 (Ang-2) have both been described as ligands for
thrombomodulin in vitro [24]. Ang-2 binds with higher
affinity than Ang-1 but both, by competing with
thrombin, can disrupt thrombomodulin–thrombin
interactions leading to suppression of thrombin-medi-
ated anticoagulant functions. Thrombomodulin bind-
ing to heat shock protein 70 (HSP70-1) on the
endothelial cell surface can also inhibit thrombomod-
ulin function in vitro by reducing protein C activation
by as yet unknown mechanisms [25]. The wide-ranging
roles of thrombomodulin in coagulation are well-docu-
mented elsewhere [24,26] and hence will not be dis-
cussed in any depth. We also direct the reader towards
a recent extensive review exploring the ‘nontraditional
roles’ of thrombomodulin [27].
Thrombomodulin and angiogenesis
Proangiogenic effects have been reported for a recom-
binant form of soluble thrombomodulin encompassing
six contiguous EGF modules and the mucin-like
region (thrombomodulinEGF-Mucin), resulting in
increased endothelial proliferation, tube formation,
migration and upregulation of matrix metalloprotease
expression in vitro [28]. This recombinant protein also
elicited proangiogenic effects on endothelial progenitor
cells (EPCs) through a phosphoinositide 3-kinase
(PI3K)-dependent pathway [29]. Furthermore, throm-
bomodulinEGF-Mucin demonstrated endothelial protec-
tive roles chiefly by guarding against apoptosis again
via the PI3K pathway [30]. These roles are thought to
be dependent on the EGF domains which can bind to
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and activate fibroblast growth factor receptor 1
(FGFR1) [31]. The fifth EGF domain of thrombomod-
ulin alone (thrombomodulinEGF5) has also demon-
strated proangiogenic function as well as
cytoprotective effects on endothelium [32]. This cyto-
protective phenomenon was suggested to be indepen-
dent of thrombomodulin–thrombin interactions and
instead due to upregulation of antiapoptotic protein
myeloid-cell leukaemia-1 (MCL1) [33]. A subsequent
study revealed that this cytoprotective outcome was
triggered by thrombomodulinEGF5 binding to G pro-
tein-coupled receptor-15 (GPR15) on endothelial cells,
leading to the activation of endothelial nitric oxide
synthase and extracellular signal-regulated kinase
(ERK) signalling, an effect that was abolished in
GPR15-deficient mice [34]. Recently, the minimal frag-
ment of thrombomodulinEGF5 necessary for binding to
GPR15 and promoting proangiogenic function was
identified as a 19-amino acid peptide, that includes an
intramolecular disulfide bond which adopts a loop
structure similar to that observed for the prototypical
EGF [31,35]. This peptide exhibited proangiogenic
function and extended survival in mouse models of
sinusoidal obstruction syndrome, a condition that is
associated with injury of liver sinusoidal endothelium
[35]. However, whether thrombomodulin can bind to
GPR15 while attached to the cell membrane, or if pro-
teolytic processing is essential, is yet to be determined.
These proangiogenic signals mediated by the throm-
bomodulin EGF5 domain can be abolished when the
soluble extracellular domain (ECD) contains the
CTLD [36]. The CTLD of thrombomodulin binds to
Lewis Y antigen, which is a cell surface tetrasaccharide
that is predominantly expressed during development
Fig. 2. Alignments of CTLD group 14 family members based on amino acid sequence. Amino acid alignments of the whole primary
sequence of each human family member using PRALINE [229]. The following protein sequences were used thrombomodulin (P07204),
CD93 (Q9NPY3), CLEC14A (Q86T13) and CD248 (Q9HCU0).
3302 The FEBS Journal 286 (2019) 3299–3332 ª 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
CTLD group 14 family K. A. Khan et al.
and tumourigenesis [37]. Relatedly, soluble CTLD
alone can mediate aberrant effects in angiogenesis
assays, presumably by virtue of its interactions with
Lewis Y antigen localised on epidermal growth factor
receptor-1 (EGFR1), thereby inhibiting its activation
[36]. These findings suggest that the thrombomodulin
CTLD exhibits roles distinct from the EGF domains
and may be functionally dominant in its soluble form,
due to its ability to negate EGF domain-dependent
effects. The CTLD of membrane-bound thrombomod-
ulin has been shown to bind to the extracellular matrix
protein fibronectin, an interaction which activates focal
adhesion kinase phosphorylation and upregulates
matrix metalloproteinase-9 (MMP9) [37,38]. The
thrombomodulin–fibronectin interaction occurs on
tumour blood vessels in murine melanoma suggesting
that this interplay may serve as a putative target for
antiangiogenic therapy, although an in-depth under-
standing of this interaction in healthy tissues would
first need to be considered. Thrombomodulin cell sur-
face expression can be regulated by binding of the
CTLD to Kringle 1–5, a proteolytically cleaved frag-
ment of plasminogen [39]. This binding event results in
thrombomodulin internalisation and degradation,
negating the proangiogenic roles of membrane-bound
thrombomodulin.
Thrombomodulin and cancer
Thrombomodulin expression has been described in
multiple cancer types on the endothelium and tumour
cells [40,41]. In genetically engineered mice expressing
a mutant form of thrombomodulin with severely
compromised thrombin binding, primary tumour
growth was unaffected whereas lung metastasis was
significantly enhanced [42]. The authors suggested
this observation was due to prolonged survival of
tumour cells in the lung and demonstrated that this
effect was attributed to the thrombin binding func-
tion and not the N-terminal CTLD. A whole host of
studies in different tumour settings (lung, colorectal,
cervical, prostate and bladder) postulate a role for
thrombomodulin overexpression in reversing epithe-
lial mesenchymal transition (EMT) [43–48]. Upregu-
lation of thrombomodulin may even enhance tumour
sensitivity to chemotherapeutic agents, such as dox-
orubicin [49]. Indeed, a more comprehensive review
of the role of thrombomodulin in tumour biology
has been documented [40]. The overall findings seem
to indicate that thrombomodulin expression corre-
lates with a good prognosis and expression is abol-
ished in more aggressive and highly metastatic
tumour types.
More recently, soluble human thrombomodulin has
been utilised as a potential cancer therapeutic agent and
reductions in tumour growth were observed when admin-
istered to mice bearing pancreatic tumour xenografts
[50]. Furthermore, the soluble ECD of thrombomodulin
has also been reported to reduce tumour growth in
inflamed models of gastrointestinal tumours [51].
Whether soluble thrombomodulin could have antitu-
mour effects in patients has not been formally investi-
gated; however, it has demonstrated clinical benefits in
managing disseminated intravascular coagulation in can-
cer patients and has the potential for direct effects on
tumour burden as well as in aberrant thrombosis [52].
Thrombomodulin and inflammation
Thrombomodulin has been described to have roles in
inflammation some of which are linked to its anticoag-
ulant function. This is best exemplified by protein C
triggering an anti-inflammatory signalling cascade by
inhibiting tumour necrosis factor-a (TNFa) production
in response to lipopolysaccharide (LPS) [53]. Indepen-
dent of its roles in coagulation inhibition, thrombo-
modulin CTLD can bind to the proinflammatory
molecule high-mobility group protein B1 (HMGB1),
leading to suppression of inflammation in vivo and
protection against LPS-induced lethality [54]. A more
recent study highlighted that the thrombomodulin–
HMGB1 interaction allows the EGF domain bound
thrombin to proteolytically cleave HMGB1 [55]. The
inactivation of HMGB1 has potential implications on
immunogenic cell death events following anticancer
intervention invoked by chemotherapeutic agents or
radiotherapy, whereby HMGB1 released by dying cells
serves as damage-associated molecular patterns acti-
vating antigen-presenting cells and facilitating presen-
tation of tumour antigens [56]. The thrombomodulin
CTLD has also been shown to reduce the adhesion of
polymorphonuclear leucocytes to endothelium [57].
The authors proposed that this process was dependent
on thrombomodulin binding to Lewis Y antigen and
therefore blocking its availability to bind leucocytes
and aid subsequent transmigration. Conversely, human
leucocytes have been suggested to directly recognise
the mucin-like region of thrombomodulin through leu-
cocyte adhesion integrins lymphocyte function-associ-
ated antigen-1 (LFA-1) and Mac-1 in vitro [58].
Thrombomodulin EGF domains were found to mark-
edly suppress LPS-induced inflammatory signalling
pathways in macrophages by associating with the pat-
tern recognition receptor CD14, and that this inhibi-
tory effect was also dependent on the serine threonine-
rich domain [59].
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ThrombomodulinEGF5 also has the capacity to engage
T-cells bearing GPR15 [60]. This results in immunosup-
pression of T-cell responses and facilitates the differentia-
tion of regulatory T-cells (Tregs). In addition,
recombinant thrombomodulinEGF5 was shown to inhibit
dendritic cell activation. Taken together, this provides a
possible rationale for recombinant thrombomodulin-me-
diated alleviation of graft versus host disease (GVHD) in
mouse models of haematopoietic stem cell transplanta-
tion [32]. More importantly, it reconciles with clinical
observations that increased expression of thrombomod-
ulin can reduce GVHD in patients [32,61]. This immuno-
suppressive role of thrombomodulin could also have
relevance in tumour immunology as thrombomodulin
expressed in the tumour microenvironment has the
potential to expand anti-inflammatory and protumour
Tregs, a cell type that contributes to tumour immune eva-
sion mechanisms [62]. However, these findings are con-
trary to observations reporting thrombomodulin as a
good prognostic factor, and its role in immunosuppres-
sion may be outweighed by its function in EMT and
aggressiveness. Thrombomodulin also exhibits anti-in-
flammatory properties by regulating the alternative path-
way of complement activation. Complement activation is
a critical process in inflammation of the innate immune
system and involves the cleavage of various proteins
resulting in proteolytic release of chemotactic factors and
activation of further cleavage events ultimately leading to
the assembly of pathogen destruction complexes [63].
Thrombomodulin–thrombin-mediated activation of
TAFI cleaves complement proteins C3a and C5a leading
to their inactivation [64] which has been demonstrated
both in vitro and in vivo [65,66]. Thrombomodulin binds
to complement protein C3b and enhances its factor H-
and factor I-mediated degradation into its inactive form
(iC3b), another mechanism of negative regulation of the
alternative complement pathway [67].
Thrombomodulin shedding
There are many transmembrane proteins that are
specifically shed from the cell membrane to activate or
deactivate distinct protein functions in angiogenesis
and other physiological processes. Examples include
the membrane-bound EGF precursor proteins, which
are cleaved by metalloproteinases such as ADAM10 (a
disintegrin and metalloproteinase-10) and ADAM17
resulting in growth factor activation [68]. Conversely,
the EGF receptor itself can be subjected to proteolytic
cleavage thereby suppressing downstream signalling
functions [69].
Thrombomodulin can be cleaved by the serine pro-
tease rhomboid-like 2 (RHBDL2) at a site proximal to
the transmembrane domain, resulting in release of the
entire ECD [70]. This RHBDL2 cleaved form of
thrombomodulin can increase migration and wound
healing in keratinocytes in vitro [71]. Also, the full-
length thrombomodulin-ECD has also been shown to
be cleaved from the endothelial cell surface after incu-
bation with the neutrophil proteases elastase, cathepsin
G and proteinase 3 [72]. Soluble thrombomodulin has
been detected in human blood, urine and synovial fluid
[73–75]. Indeed, monitoring serum levels of soluble
thrombomodulin may be important as it can positively
correlate with disease status such as systemic lupus
erythematosus [76].
The thrombomodulin CTLD can also be cleaved
leaving the remainder of the molecule intact upon the
cell surface, an event that is most likely facilitated by
matrix metalloproteinases (MMPs) [77]. Although,
these cleavage events are yet to be explicitly shown
in vivo, it is noteworthy that two forms of thrombo-
modulin have been isolated from human urine [74].
Characterisation of these fragments by N-terminal
sequencing revealed that one form encompasses the
EGF repeats and the mucin-rich region and retained
the ability to bind thrombin. In contrast, the second
fragment corresponded to the equivalent molecular
weight for the N-terminal CTLD and failed to bind
thrombin. Furthermore, four different versions of
thrombomodulin were detected in human plasma sug-
gesting even more potential cleavage sites [78]. Indeed,
the physiological relevance of these different fragments
requires further investigation. Although not resulting
in shedding, neutrophil proteases have been shown to
inactivate human thrombomodulin by oxidation of a
key methionine between EGF4 and EGF5 [79].
In summary, these findings of differential shedding
along with the distinct biological function of each
thrombomodulin subdomain offers a scenario where
one molecule can be proteolytically processed in differ-
ent ways to elicit opposing effects. The shedding of
thrombomodulin is likely a tightly regulated process in
which specific domains are released depending on the
requirement for pro or antiangiogenic signals, as well
as pro or anti-inflammatory outcomes.
Additional roles for thrombomodulin
Along with its vital roles in regulating blood coagula-
tion and inflammation, thrombomodulin also report-
edly contributes to cell–cell adhesion in vitro, an event
which is dependent upon the CTLD [80]. This proad-
hesion role was Ca2+ dependent and could be abol-
ished with CTLD-specific antibodies or addition of
mannose, chondroitin sulfate A or C. This suggests
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that the thrombomodulin CTLD serves as a conven-
tional Ca2+-dependent carbohydrate-binding lectin.
The cytoplasmic tail of thrombomodulin has been
proposed as a ligand for the intracellular adaptor pro-
tein ezrin [81], a member of the ezrin-radixin-moesin
(ERM) family of proteins that link transmembrane
proteins to the actin cytoskeleton [82]. This reinforces
the likelihood of thrombomodulin-mediating cell adhe-
sion events. Consistent with this, knockdown of
thrombomodulin can compromise the integrity of E-
cadherin-mediated cell–cell contacts, potentially impli-
cating thrombomodulin downregulation in the induc-
tion of EMT in cancer [43]. A summary of
thrombomodulin protein interactions is displayed in
Fig. 3.
CD248
CD248 also known as endosialin or tumour endothe-
lial marker-1 (TEM-1) is the prototypical member of
the CTLD group 14 family. It was first discovered as
an antigen detected by the antibody FB5, which
stained human tumour sections with patterns resem-
bling blood vessels, but not healthy tissues [8]. This led
the authors to describe CD248 as a marker for tumour
endothelium, although it could not be detected in cul-
tured human umbilical vein endothelial cells
(HUVEC). The study did however demonstrate that it
was a highly glycosylated cell surface glycoprotein
leading to its proposed name at the time; endosialin.
CD248 was later identified as a marker of tumour
endothelium in studies involving serial analysis of gene
expression of vessels purified from human colorectal
cancers in comparison to healthy colon vessels, hence
its alternative name TEM-1 [83]. Despite this, it is now
widely accepted that CD248 is expressed by perivascu-
lar cells, stromal fibroblasts (especially in cancer and
inflammation), mesenchymal stem cells and some
tumour cells but not adult endothelium [84–86]. The
expression of CD248 on perivascular cells but not on
endothelium in vivo was unequivocally demonstrated
using multiple fluorescent labelling of human glioma
sections [87]. The study by St. Croix and colleagues
which originally identified CD248 as TEM-1 utilised
CD146 or melanoma cell adhesion molecule (MCAM)
antibodies to enrich the endothelium. Since MCAM
also serves as a marker for pericytes, these samples
likely contained perivascular cells as well as endothe-
lium explaining the enrichment of CD248 [84,88]. The
proposed expression of CD248 on EPCs may have also
added to this confusion [89].
CD248 expression
CD248 is expressed during development and is first
detected in mice at embryonic day 9.5 [90]. CD248
expression is mostly diminished in postnatal organs
except for the kidney glomeruli and the uterus. Mice
deficient in CD248 are viable and display no obvious
defects, suggesting compensatory mechanisms may be
employed during development [91]. However, a
marked decrease in tumour growth, metastasis and
invasion was observed when CD248 deficient mice
were challenged with human colorectal cancer xeno-
grafts. This defect in tumour growth and metastasis
was only evident with abdominally implanted tumour
Coagulation
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Ezrin
F-actin
Fibronectin
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Coagulation
Migration
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Fig. 3. Schematic of thrombomodulin
protein structure with ligand binding
partners. Thrombomodulin CTLD has been
shown to interact with fibronectin, HMGB1,
Kringle 1–5, Lewis Y antigen and HSP70-1.
The CTLD may be proteolytically cleaved by
an as yet unidentified MMP. Thrombin
binds to the 5th and 6th EGF domains, this
binding is in competition with Ang1 and/or
Ang2. RHBDL2 can cleave the whole ECD
of thrombomodulin as can neutrophil
elastase, cathepsin G and proteinase 3. The
cytoplasmic tail binds to ezrin which in turn
links thrombomodulin to the actin
cytoskeleton.
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cells, whereas subcutaneous implants displayed no dif-
ference relative to control animals. Further studies
revealed that expression of CD248 exhibited negligible
effects on primary tumour growth but increased metas-
tasis formation in mouse models of breast cancer [92].
Such prometastatic effects were attributed to CD248
expressing pericytes enhancing tumour cell intravasa-
tion. Elevated-CD248 expression also correlated with
greater metastasis and poorer survival in human breast
cancer patients.
CD248 expression has been reported to be induced
by hypoxia, predominantly involving the transcription
factor hypoxia inducible factor-2a (HIF-2a) [93]. This
could explain the high levels of CD248 observed in the
tumour microenvironment which is often poorly per-
fused and contains areas of hypoxia [94]. Upregulation
of CD248 can also arise in response to the growth fac-
tors FGF-2, EGF and platelet-derived growth factor-
BB (PDGF-BB), which is further enhanced under
hypoxic conditions [95].
CD248 expression has been described on na€ıve human
CD8+ T-cells, where it can negatively regulate prolifera-
tion [96]. CD248 is expressed on stromal cells in sec-
ondary lymphoid organs and is required for correct
secondary lymph node expansion in models of vaccina-
tion [97]. However, CD248 was not essential for correct
spatial organisation of T and B cells in this model.
CD248 interaction partners and
biology
CD248 has been reported to interact with the ECM
proteins fibronectin and collagens I and IV [98]. The
interaction of CD248 with fibronectin increased cell
adhesion of Chinese hamster ovary (CHO) cells over-
expressing CD248 and was dependent upon the N ter-
minus of fibronectin and the CTLD of CD248.
Consistent with these data, the CTLD-specific mono-
clonal antibody MORAb-004 (ontuxizumab) could
block CD248 binding to fibronectin and collagen I.
Also, siRNA-mediated knockdown of CD248 resulted
in reduced migration and proliferation of fibroblasts,
reinforcing a putative role in adhesion [99]. Interest-
ingly, a characteristic feature identified in CHO cells
overexpressing CD248 is the upregulation of MMP9,
thereby implicating CD248 in ECM degradation, a
key step in sprouting angiogenesis as well as tumour
metastasis and invasion [98]. Further evidence in sup-
port of CD248 associating with the ECM stemmed
from immunofluorescent staining with CD248 ECD
fused to an Fc tag (CD248-ECD-Fc), this staining was
only observed in the ECM from endothelial cells
(HUVEC) and could partially co-localise with
fibronectin [100]. More recently, we have shown direct
interaction of CD248 with the endothelial ECM pro-
tein multimerin-2 (MMRN2) [101]. This interaction
was dependent upon the CTLD of CD248 and
CD248-ECD-Fc staining could partially co-localise
with MMRN2 on HUVEC; this may clarify previous
findings involving the CD248-ECD binding to the
endothelial ECM [100].
Another ligand identified for CD248 was the
secreted galectin-3 (Mac-2) binding protein Mac-2BP
and this interaction proved to be carbohydrate and
Ca2+ independent [102]. The CD248 interaction was
mapped to two C-terminal domains of Mac-2BP and
these have been previously implicated in binding galec-
tin-3, collagens V and VI, and nidogen, suggesting
overlapping binding sites [103]. This interaction
invokes repulsion of human fibroblasts and HeLa cells
expressing CD248 and Mac-2BP, respectively. More-
over, this phenomenon was reduced following siRNA
induced gene-silencing of either molecule. Mac-2BP is
upregulated in the tumour cells of many different types
of cancer and has been associated with increased
metastasis and decreased survival in lung cancer
patients [104]. These findings strengthen the likelihood
of CD248-Mac-2BP interactions occurring during
tumorigenesis. It is currently unknown whether the
therapeutic antibody ontuxizumab can block CD248
binding Mac-2BP or MMRN2, a question that will
likely impact novel future clinical interventions that
target CD248.
There is evidence to suggest that the cytoplasmic tail
of CD248 is involved in tumour development, as mice
lacking this domain display reduced tumour growth in
T241 fibrosarcomas and Lewis lung carcinomas (LLCs)
[105]. The cytoplasmic tail has also been predicted to
contain a PDZ binding site and three potential phos-
phorylation sites, although to date identification of
CD248 intracellular domain interactors have proved
elusive [85,106]. A summary of CD248 protein interac-
tions is summarised in Fig. 4.
CD248 implications in angiogenesis
The role of CD248 in angiogenesis is complex and there
is evidence to suggest it can both promote and inhibit
angiogenesis depending on the circumstances. When
CD248 is overexpressed in HeLa cells (normally lacking
expression of the protein), multiple pro and antiangio-
genic molecules are produced [95]. CD248-deficient mice
displayed no gross defects in developmental angiogene-
sis or wound healing, but abnormalities were clearly
apparent in tumour models of both the full gene dele-
tion and the cytoplasmic deletion, resulting in smaller
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tumours exhibiting increased vessel density, although
larger vessels were reduced [91,105]. Curiously, defects
in tumour growth were not observed in all tumour mod-
els and the underlying mechanism remains unclear.
Increased vascularity is also found in CD248-deficient
mouse models of glioblastoma multiforme, but there are
no differences in tumour growth compared to wild-type
animals [107]. These observations of increased vessel
density may be rationalised by findings connecting
CD248 with regulation of vascular patterning [87]. This
function of CD248 was uncovered when HUVEC trea-
ted with plate bound CD248 (to mimic pericyte expres-
sion), exhibited higher levels of apoptosis. This study
highlighted the prospect of CD248 mediating a key role
in vessel regression and pruning and emphasised for the
first time that pericytes could be linked to such func-
tions. Therefore, such defects in vascular pruning can
result in an increase in microvessels that may have aber-
rant function. Moreover, these observations underline
the possible therapeutic potential of the CD248-ECD
for inducing vessel regression and vascular normalisa-
tion, which might conceivably increase the delivery of
chemotherapeutic agents into tumour tissue [108]. Like-
wise, this vessel normalisation effect has been shown to
allow more efficient infiltration of effector immune cells
into tumours [109].
CD248 has also been implicated in the platelet-
derived growth factor (PDGF) signalling cascade [110].
For example, following CD248 knockdown in peri-
cytes, PDGF-mediated proliferation is reduced in vitro.
Furthermore, CD248 knockout mice displayed defects
in sprouting angiogenesis but not splitting (intussus-
ceptive) angiogenesis in skeletal muscle [111]. Such
defects could be recapitulated in mice treated with
PDGFRb inhibitors reinforcing a role for CD248 in
PDGF signalling.
CD248 in cancer
Elevated CD248 expression levels on tumour-associ-
ated stroma have been reported in various primary
tumour types including glioma, colorectal, melanoma
as well as brain metastases [87,112–114]. CD248
expression has also been associated with worse out-
come in patients with breast or colorectal cancer and
could serve as a prognostic marker [115,116]. CD248
is expressed in numerous tumour cell lines and clinical
samples of sarcomas and neuroblastomas, but is
absent in cancer cells of epithelial origin [86]. Indeed,
highly malignant ‘side population’ sarcoma cells with
some characteristics of cancer stem cells express
CD248 [117]. These highly invasive side populations
are also CD248+ in osteosarcoma [118]. For these rea-
sons, there has been a substantial drive into developing
innovative strategies of targeting CD248 for tumour
therapy.
Targeting CD248 has been attempted mainly by anti-
body-based therapeutic approaches. One of the first pre-
clinical attempts utilised single-chain variable fragment
(scFv) antibody-like molecules generated against CD248
to successfully direct cytotoxic agents to neuroblastoma
cells in vitro [119]. Internalising antibodies against
CD248 coupled with anti-human IgG toxin-conjugated
antibodies revealed cell cytotoxic effects on CD248
expressing cancer cell lines in vitro [86]. Such antibodies
were developed as full antibody-drug conjugate (ADC)
molecules utilising conjugation to tubulin-inhibiting
drugs [120]. Administration of these ADCs retarded
tumour growth in multiple xenograft models. Another
ADC against CD248 has been developed conjugated to
a DNA-binding duocarmycin derivative which has
shown therapeutic efficacy in a human osteosarcoma
xenograft model [121]. The previously described CTLD-
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Fig. 4. Schematic of CD248 structure with
ligand binding partners. CD248 CTLD binds
to fibronectin, Mac-2 BP, Collagens I and IV
and MMRN2. There are currently no known
direct intracellular interaction partners for
CD248.
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specific CD248 antibody ontuxizumab has been utilised
as a possible diagnostic imaging tool through use of
125Iodine conjugation and positron-emission tomogra-
phy [122]. This technique resulted in rapid tumour
uptake and real-time visualisation of tumour burden and
CD248 localisation in mice. Some more recent develop-
ments have involved the generation of human CD248
knock-in mice to study the in vivo effects of ontux-
izumab [123]. Indeed, upon administration of ontux-
izumab into B16 melanoma-bearing mice, tumour
growth was significantly reduced by up to 70%. This
was presumably due to increase in microvessel density
and the presence of nonfunctioning tumour blood ves-
sels; phenocopying previous findings in CD248 knockout
animals. This study also showed downregulation of sur-
face expression of CD248 on pericytes by internalisation
after ontuxizumab treatment in vitro and in vivo. Despite
some preclinical efficacies, the ontuxizumab-humanised
CD248 antibody has recently completed two phase II
clinical trials which failed to show improvements from
standard of care or placebo in metastatic colorectal can-
cer and neglected to meet a progression-free survival
(PFS) goal of 35% in metastatic melanoma [124,125] No
clinical benefit was also observed in phase II trials
involving metastatic soft tissue sarcoma treated with a
combination with ontuxizumab and chemotherapy
(gemcitabine and docetaxel) [126].
DNA vaccine approaches against CD248 have also
been attempted preclinically, with antitumour effects
being reported in both the prophylactic and therapeu-
tic vaccine setting [127]. The DNA construct consisted
of murine CD248 fused to a fragment of tetanus tox-
oid, which circumvents tolerance to the self-protein
allowing triggering of an adaptive immune response.
The authors described CD4+ and CD8+ T-cell clones
that were specific for CD248 epitopes as well as
tumour specific antigens. The vaccination did not
detrimentally affect wound healing or reproduction.
The targeting of CD248 may even be detrimental in
some tumour types, as CD248 expression upregulated in
hepatocellular carcinoma (HCC) patients in hepatic stel-
late cells (specialised pericytes found in the liver vascula-
ture) was found to be protective correlating with better
outcomes [128]. Furthermore, inducible models of HCC
in CD248 knockout mice displayed enhanced liver
tumour progression relative to wild-type controls.
CD248 in inflammation and fibrosis
CD248 is expressed in mesenchymal stromal cells of
developing mouse lymphoid tissues such as the
spleen, thymus and lymph nodes [129,130] expression
in the adult mouse spleen is low, but is enhanced in
stromal cells upon Salmonella enterica infection coin-
ciding with spleen remodelling and repair [129].
CD248 expression in mice is required for postnatal
development of the thymus as well as regeneration of
the thymus after S. enterica infection, in CD248 defi-
cient animals this postinfection regeneration is
impaired [130].
CD248 is expressed in vascular smooth muscle cells
(VSMCs) undergoing proliferation and remodelling in
apolipoprotein-E (ApoE) KO mouse models of
atherosclerosis as well as atherosclerotic lesions from
patients [131]. CD248 was shown to promote
atherosclerosis as ApoE and CD248 double KO mice
displayed less atherosclerosis when fed a Western style
diet. These CD248-deficient animals also exhibited
marked reductions in macrophage infiltration into
atherosclerotic plaques, due to reduced chemokine
expression in VSMCs. Reduced macrophage recruit-
ment in CD248 KO mice was also shown in other
models of inflammation not involving atherosclerosis.
CD248 is expressed in the fibroblasts and pericytes
of synovial tissue from patients with rheumatoid
arthritis and psoriatic arthritis [132]. CD248 expression
has also been identified in the sublining layer of a dis-
tinct subset of synovial fibroblasts [133]. CD248
knockout mice and mice lacking the cytoplasmic
domain of CD248 both showed reductions in experi-
mental arthritis compared to wild-type animals, and
displayed a marked reduction in synovial inflammation
[132]. CD248 also has roles in bone formation, it is
expressed by bone forming osteoblasts but not bone
removing osteoclasts in both mice and humans [134].
CD248 knockout mice display denser bones most
likely due to the hyperactivation of osteoblasts and
increased mineral formation that would normally be
inhibited by PDGF signalling, which is disrupted in
CD248-deficient cells. These findings suggest that tar-
geting CD248 therapeutically may not only reduce
inflammation in arthritis but also reduce bone loss
associated with arthritis.
CD248 is expressed in healthy human and mouse
kidney mainly in the mesangial cells of the glomerulus,
but also in pericytes and fibroblasts. CD248 is upregu-
lated in chronic kidney disease and inflamed kidney on
a population of myofibroblasts and may be a useful
predictor of renal failure [135]. CD248 was later shown
to have a potential role in the development of kidney
fibrosis in mice [136,137]. CD248-deficient mice under-
going renal damage were protected against fibrosis,
this was not as a result of reduced inflammation but
possibly due to CD248 KO fibroblasts producing less
collagen and CD248 KO pericytes displaying impaired
differentiation into myofibroblasts (a major cell type
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involved in fibrosis). Similar to fibrosis in kidney,
CD248 deficiency also protected mice against liver
fibrosis following liver injury, and these KO mice dis-
played reductions in collagen but no change in inflam-
mation [138]. CD248 expression was also detected in
human samples of liver fibrosis on myofibroblasts and
perivascular cells and was elevated in human liver
fibrosis samples compared to healthy controls as well
as correlating with levels of collagen deposition. Idio-
pathic pulmonary fibrosis patients also display high
expression of CD248 in fibroblasts and it may serve as
a disease severity marker [139].
CD248 has also been described as being highly
expressed in skin samples of patients with systemic
sclerosis in comparison to healthy controls [140].
When CD248 expression was silenced by means of
siRNA in mesenchymal stem cells from systemic scle-
rosis patients, TGF-b and PDGF profibrotic signalling
was reduced.
These described roles of CD248 promoting aberrant
inflammation and fibrosis suggest it may be a suitable
therapeutic target in certain diseases. However, it is
possible that such CD248 inhibition may also have
detrimental effects on lymphoid tissue remodelling and
repair following infection.
CD248 shedding
There are numerous reports describing soluble variants
of CD248, suggesting its ECD may be shed from the
cell surface as highlighted for other CTLD group 14
family proteins. CD248 has been suggested as a possi-
ble biomarker after it was purified from ascites fluid of
patients with stage IV ovarian cancer [141], and pan-
creatic cancer [142]. CD248 can be immuno-precipi-
tated from human serum in a fully glycosylated form
of around 150–120 kDa, likely corresponding to the
full ECD [143]. In this same study, a highly sensitive
and specific assay was developed using two different
CD248 monoclonal antibodies to evaluate CD248
levels in patient blood. However, there was no signifi-
cant difference in serum levels of soluble CD248 from
colorectal cancer patients compared with healthy con-
trols, which may limit its utility as a predictive biomar-
ker particularly in this tumour setting. A protease
capable of cleaving CD248 from the cell surface has
yet to be identified.
CD93
CD93 was first described as a receptor for the comple-
ment component C1q, hence its alternative name C1q
receptor-1 (C1qR1 or C1qRp) [144,145]. A subsequent
study revealed that CD93 failed to engage C1q, but
was instead implicated in cellular adhesion events
[146]. CD93 is expressed predominantly by endothelial
cells and has been reported to be expressed by neurons
in a rat model of inflammation and various cells of the
haematopoietic system, including monocytes, neu-
trophils, B cells, natural killer (NK) cells, na€ıve T-cells,
platelets and haematopoietic stem cells [147–152]. It is
also highly expressed on the tumour-associated vascu-
lature. In a recent example, elevated levels of CD93
expression were detected on human colorectal carci-
noma sections [153]. Interestingly, this study also
examined soluble levels of CD93 within patient plasma
and found a 30% reduction in colorectal carcinoma
patients compared with healthy controls. CD93 has
been described as a key gene in a proposed ‘tumour
angiogenesis signature’ determined by meta-analysis of
959 breast cancers, 170 renal cancers and 121 head
and neck cancers [154]. Moreover, CD93 has been
identified as a member of a group of genes that are
vastly upregulated in high-grade glioblastoma tumour
vasculature [155]. This high expression profile was later
confirmed at the protein level and correlated with
poorer survival [156]. Upregulated vascular expression
of CD93 has also been described in nasopharyngeal
carcinoma, as well as tumours of the eye including
retinoblastoma and choroidal melanoma [157,158], and
correlates with a worse survival outcome. More
recently, the CD93 CTLD has been derived from
Escherichia coli expression systems that allow disulfide
bond formation and has been purified to homogeneity
allowing preliminary structural analyses using nuclear
magnetic resonance approaches [159]. This study
revealed the CD93 CTLD does not bind Ca2+ and
ongoing experiments will undoubtedly resolve the
three-dimensional structure and provide further molec-
ular and functional insights into this family member.
CD93 expression
During mouse development CD93 is expressed at
embryonic day 9 and is detected in the vasculature
including the inter-segmental vessels [160]. CD93-defi-
cient mice were viable and displayed no obvious
abnormalities, but macrophages from deficient mice
exhibited reductions in phagocytosis and reduced
clearance of apoptotic cells in both in vivo and in vitro
apoptotic clearance assays [161]. A defect in antibody
secretion in plasma cells was also a characteristic fea-
ture of CD93 knockout mice [152]. Intriguingly, only
CD93-deficient female mice display aberrations in
tumour growth and perfusion in orthotopic glioblas-
toma and fibrosarcoma models [156].
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CD93 interaction partners and biology
Silencing of CD93 by RNA interference in HUVEC-
impaired proliferation, migration, adhesion and sprout
formation [162]. Subsequent studies validated these
effects with disruptions observed in adhesion, migra-
tion and tube formation [156,157]. A monoclonal anti-
body raised against human CD93 (clone 4E1) which
binds between the CTLD and sushi domains demon-
strated antiangiogenic activity in Matrigel assays both
in vitro and in vivo, reiterating its roles in endothelial
biology [162]. CD93 has been identified as a gene that
is downregulated upon VEGF blockade by using beva-
cizumab in patented studies performed by Genentech
[163]. Similarly, another report highlighted that CD93
protein expression was diminished upon pharmacologi-
cal inhibition of VEGFR2 and fibroblast growth fac-
tor-1 with brivanib alaninate [164]. While VEGF could
be having effects on CD93 independent of angiogene-
sis, the loss of function experiments involving CD93
seem to steer towards a proangiogenic function.
Ligand binding studies of CD93 with a variety of
ECM proteins revealed a lack of binding to all pro-
teins tested in vitro including; collagen I and IV, gela-
tin, laminin, vitronectin and fibronectin [165]. The
only known extracellular interacting partner for CD93
was recently identified as the endothelial specific ECM
protein MMRN2 [101]. This interaction is dependent
on the CTLD of CD93 and by combining structural
modelling with site-directed mutagenesis a predicted
long-loop region of this structure was proposed to be
critical for binding to MMRN2. This offers a platform
for developing innovative therapeutics that specifically
target CD93 to interrupt this interaction. The CD93-
MMRN2 interaction was later independently validated
and surface plasmon resonance was used to charac-
terise the interaction and determine binding affinities
[166]. A key residue within the coiled-coil domain of
MMRN2 (F238) was proposed as being integral for
CD93 binding. Interestingly, this study also provided
an explanation for the previously described antiangio-
genic effects of the CD93 antibody 4E1, as it could
interrupt the CD93-MMRN2 interaction.
The CD93-MMRN2 interaction was also shown to
be involved in the proper deposition and organisation
of fibronectin a process termed fibrogenesis [167]. In
CD93-deficient mice the fibronectin matrix was dis-
rupted in vessels of postnatal retinas and vessels in
orthotopic models of glioblastoma [167]. In the same
study, the use of specific antibodies that detect acti-
vated a5b1 integrins revealed disruption of this acti-
vated integrin in CD93 knockout mice. During
postnatal retinal angiogenesis, CD93 is expressed on
filopodia while MMRN2 expression is absent from
these protrusions but present in the surrounding ECM.
Finally the authors showed that MMRN2 and fibro-
nectin expressions are upregulated in high grade
human glioma [167]. Co-localisation of CD93 and
MMRN2 expressions has been demonstrated in vessels
of a range of different solid human tumours including
melanoma, Ewing’s sarcoma, ovarian carcinoma and
glioma amongst others [166,167]. There are likely other
partner proteins for CD93 as a study showed that the
recombinant form of the CD93 ECD can engage the
cell surface of THP-1 cells indicating the expression of
a currently unknown CD93 ligand in this monocyte
cell line [168].
The cytoplasmic domain of CD93 encompasses a
positively charged juxtamembrane region that binds to
the adaptor protein moesin [169]. Moesin is a member
of the ERM family of proteins, which like ezrin and
radixin, anchor proteins to the actin cytoskeleton [82].
In knockdown studies involving CD93, adherens junc-
tions were disrupted [156]. Strikingly, reintroduction of
wild-type CD93 but not CD93 lacking the moesin bind-
ing motif, restored adhesion junctions and highlighted
the importance of CD93-moesin interactions in main-
taining the integrity of endothelial cell adhesion
in vitro. Relatedly, CD93-deficient mice display
increased permeability in blood vessels possibly due to
disruptions in tight junctions [170]. Another intracellu-
lar binding partner for CD93 has been defined as
GIPC, (Ga interacting protein (GAIP)-interacting pro-
tein C-terminus), [171] an adapter protein that con-
tributes to arterial maturation and mural cell coverage
[172]. The binding of GIPC was dependent on the posi-
tively charged juxtamembrane as well as the final C-ter-
minal 11 amino acids of the cytoplasmic tail. CD93
was originally predicted to bind to the E3 ubiquitin
ligase Cbl, due to the CD93 cytoplasmic domain con-
taining a binding motif that is also found in the Cbl
binding protein APS (adapter with pleckstrin homol-
ogy and Src homology-2 domains) [173]. CD93 binding
to Cbl was proved experimentally by co-immunoprecip-
itation in HUVEC, and this interaction was abolished
upon knockdown of the ECM adhesion molecule b-
dystroglycan [165]. This study proposed that the cross-
talk between the laminin-binding protein b-dystrogly-
can and CD93 led to endothelial cell adhesion and
migration. The authors suggested that upon laminin
binding to b-dystroglycan src kinase phosphorylates
specific tyrosine residues in the cytoplasmic tail of
CD93, which in turn facilitates binding to Cbl. In this
setting, Cbl may serve as an adapter protein rather
than a ubiquitin ligase. A summary of the protein inter-
action partners of CD93 are summarised in Fig. 5.
3310 The FEBS Journal 286 (2019) 3299–3332 ª 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
CTLD group 14 family K. A. Khan et al.
CD93 and inflammation
Mice deficient in CD93 when subjected to experimental
peritonitis displayed increased leucocyte infiltration,
and this effect was not restricted to a particular cell
type [170]. CD93 also has been suggested to have neu-
roprotective roles and as it is upregulated in murine
models of stroke [174]. This upregulation effect was
also observed at the protein level in several cell types
including endothelial cells, microglia and macrophages.
Moreover, cerebral ischaemia in CD93 knockout mice
resulted in enhanced neuro-inflammation compared to
wild-type animals. CD93 knockout mice also displayed
increased brain and spinal cord inflammation when
compared to wild-type mice in two different models of
encephalomyelitis [175]. Based on the CD93 expression
profile within the tumour vasculature and its potential
anti-inflammatory roles, it is plausible to contemplate
that CD93 may serve as an immunosuppressive mole-
cule in the tumour microenvironment, limiting immune
cell infiltration and facilitating tumour immune eva-
sion mechanisms.
CD93 shedding
Soluble CD93 has been detected in human plasma,
described to be a protein released from HUVEC and
also a component of their ECM [171,176,177]. Several
studies have highlighted that levels of soluble CD93
directly correlate with disease status; in plasma it has
been proposed as a potential biomarker for coronary
artery disease and is elevated in synovial fluid of
rheumatoid arthritis patients [168,178]. In another
study, soluble CD93 was proposed as a marker for
inflammation as it is reportedly shed from the cell sur-
face of monocytes and neutrophils, which is likely to
be dependent on metalloproteinases, although the
major sheddase ADAM17 is not involved [179]. This
cleavage event most likely liberates the entire ECD of
CD93 and can be stimulated by TNFa or LPS. This
inflammation induced shedding of CD93 was subse-
quently confirmed by in vivo experiments, and macro-
phages were suggested as the main source of soluble
CD93 [180]. Conversely, elevated levels of soluble
CD93 in peritonitis fluid were shown to be dependent
on nonhaematopoietic cells, likely from endothelium
[170]. Soluble CD93 has been suggested to induce dif-
ferentiation of monocytes by as yet undefined mecha-
nisms [168]. A role for soluble CD93 in the process of
efferocytosis has been proposed, whereby cleaved
CD93 binds to apoptotic cells via the CTLD in a Ca2+
independent manner [181]. Soluble CD93 then acts as
an opsonin-coating apoptotic cells and is in turn
bound by axb2 integrin on macrophages via the CD93
EGF repeats aiding phagocytosis.
Soluble recombinant CD93 encompassing solely the
five tandem EGF repeats and mucin domain of CD93
mediate proangiogenic effects on endothelial cells,
increasing proliferation and migration of HUVEC and
promoting angiogenesis in vivo [182]. Although these
proangiogenic signals were also induced with the full-
length CD93-ECD, constructs lacking the CTLD eli-
cited more potent effects by enhancing the EGFR1
mediated PI3K signalling pathway; similar results were
observed with recombinant soluble forms of thrombo-
modulin encompassing the EGF and mucin domains
[36].
The O-glycosylation modifications within the mucin-
like domain of CD93 contribute to stabilising its cell
surface expression [183]. Intriguingly, the lack of O-
linked glycosylation enhanced proteolytic cleavage of
CD93 from the cell membrane and increased levels in
culture medium. This provides a possible role for the
mucin-like region within all the CTLD group 14 fam-
ily members in preventing proteolytic cleavage, and
also offers a potential mechanism of modulating sur-
face cleavage events. The cell-surface expression of
CD93 is regulated by protein kinase C isoenzymes
[184], and shedding could be enhanced by phorbol 12-
myristate 13-acetate (PMA), a potent activator of pro-
tein kinase C [185].
Upon knockdown of MMRN2, together with inhibi-
tion of new protein synthesis by cycloheximide treat-
ment, cell surface CD93 levels were shown to be
diminished whereas soluble CD93 levels increased
[167]. This suggests that the interaction with MMRN2
may render CD93 less susceptible to proteolytic cleav-
age and hence this recognition event is important for
regulating stable cell surface expression of CD93.
Additional roles for CD93
A study examining CD93 expression in neurons and
microglia revealed that upon response to LPS mediated
inflammation, the cytoplasmic tail of CD93 could be
detected in the cytoplasm and nucleus [148]. This is the
first instance that a possible gene expression modulating
role has been inferred for the CD93 cytoplasmic region.
As CD93 ECD cleavage is enhanced by LPS, and the
cytoplasmic domain can be detected even after cleavage
[171], it is possible that it translocates to the nucleus
after ECD shedding, similar to that described for notch
ECD [186]. The authors did not confirm whether
nuclear localisation followed CD93 ECD cleavage and
further work is warranted in order to define the precise
molecular mechanisms underlying this effect. Notably,
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similarities have been proposed between CD44 and
CD93 [171] as the CD44 ECD can be cleaved by
ADAM10 and its intracellular domain by c-secretase,
similar to that described for notch receptors [187].
CLEC14A
C-type lectin family 14 member A (CLEC14A) is a
type-I single-pass transmembrane glycoprotein and
considered to be endothelial specific. It was described
as a novel endothelial-specific gene identified by
microarray analysis and data mining, and referred to
as an unidentified expression sequence tag (EST; acces-
sion number AW770514) [188]. CLEC14A was initially
classified as a tumour endothelial marker based on
immunohistochemical staining of multiple distinct
tumour types, with strong staining on tumour-associ-
ated vessels in contrast to a near absence of staining in
healthy tissues [189]. Upregulation of CLEC14A at the
mRNA level was also described in nonsmall cell lung
cancer (NSCLC) tissues compared to healthy lung
[190]. Interestingly, high expression of CLEC14A in
this cancer type correlated with improved clinical out-
comes. A further study indicated that the methylation
status of CLEC14A strongly correlated with its expres-
sion levels in NSCLC, and CLEC14A protein levels
were reduced in tumour tissues compared to healthy
adjacent tissue [191]. Similar to CD93, CLEC14A was
described as a key gene in a proposed ‘tumour angio-
genesis signature’ determined by meta-analysis of over
1000 tumour samples including breast, renal and head
and neck cancers [154]. It was subsequently found to
be upregulated at the protein level and increased with
tumour progression in two different spontaneous
mouse tumour models, namely cervical and pancreatic
[177]. More recently, CLEC14A overexpression on the
vasculature in ovarian cancer has been reported but
did not correlate with survival in this tumour type
[192]. The authors also demonstrated that CLEC14A
expression was undetectable along with reductions in
microvessel density in patients receiving neoadjuvant
chemotherapy prior to surgery.
CLEC14A expression
CLEC14A (or C1qrl in zebrafish) is thought to be
located downstream of the master endothelial and
haematopoietic regulatory transcription factor etsrp
in zebrafish (ETV2 in humans) [193]. The etsrp
transcription factor has recently been implicated in
tumour angiogenesis in xenograft models of mela-
noma and sarcoma in zebrafish embryos [194]. Dur-
ing zebrafish development, clec14a is expressed at
24 h postfertilisation and morpholino knockdown of
gene expression can have detrimental effects on vas-
culature formation [189]. Interestingly, following
reintroduction of human CLEC14A mRNA into
these knockdown zebrafish embryos, the vasculature
reverted back to a normal phenotype showing the
correct zebrafish homologue was targeted and high-
lighting the conserved nature of these genes. Zebra-
fish homozygous for clec14a null alleles develop
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Fig. 5. Schematic of CD93 structure with
ligand binding partners. CD93 CTLD binds
to MMRN2. The whole ECD has been
shown to be cleaved by an as yet
unidentified metalloproteinase. The
intracellular cytoplasmic domain binds to
moesin which in turn links CD93 to the
actin cytoskeleton. The cytoplasmic domain
also binds to Cbl and GIPC1 and src.
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normally into viable adults [195], these zebrafish as
embryos do however display delays in vasculogene-
sis and angiogenesis, and these defects can be
heightened with knockdown of C1qr/CD93.
Mouse embryos display expression of CLEC14A in
inter-segmental vessels and vessels in the developing
brain, at embryonic day 10.5 [196]. Expression was
also detected in the vessels of mouse retinas at postna-
tal day 12, which are constantly undergoing develop-
ment after birth. CLEC14A has also been described as
being upregulated when EPCs differentiate into out-
growth endothelial cells [197]. Despite early expression
in embryogenesis, CLEC14A is not completely critical
to angiogenesis as CLEC14A deficient animals develop
normally with no gross defects in vessel formation.
CLEC14A has been described to be upregulated by
low shear stress [189]. Indeed, upon application of
2 pascal (Pa) of flow induced laminar shear stress to
HUVEC in culture, this leads to a significant reduction
(> 90%) of CLEC14A expression when compared to
static culture (low shear stress). This may explain the
expression of CLEC14A observed within the ill-formed
vessels of tumours that experience irregular blood flow
and low shear stress [198]. Upstream regions of the
CLEC14A gene in humans contain predicted Sp1 tran-
scription factor binding sites. Interestingly, Sp1 is phos-
phorylated in response to shear stress and can inhibit
the expression of membrane type-I matrix metallopro-
teinase (MT1-MMP) in endothelium [199]. Microarray
analysis of atherosclerosis patient samples revealed
upregulation of CLEC14A in vessels that display high
levels of stenosis [200]. This is consistent with previous
findings, as shear stress is lower in blood vessels con-
taining atherosclerotic plaques when compared with
healthy controls [201]. CLEC14A expression has also
been linked with hypoxia in HUVEC, and could explain
its greater expression in the tumour vasculature [202].
CLEC14A expression has been demonstrated in two
different human lung cancer cell lines in vitro and
when CLEC14A was further overexpressed in these
cell lines, this led to reductions in proliferation, migra-
tion and invasion as well as reductions of in vivo
tumour formation as xenografts in nude mice [191].
However, the physiological relevance of CLEC14A
expression in tumour cells themselves remains to be
seen as such expression has not been reported in clini-
cal specimens or in tumour cells by any other group.
CLEC14A roles in vascular biology and
cancer
The involvement of CLEC14A in angiogenesis is rein-
forced by in vivo experiments performed in homozygous
CLEC14A knockout mice [203]. These mice remained
viable and displayed no gross developmental defects.
Nevertheless, when challenged with subcutaneous LLC,
tumour growth and tumour angiogenesis were reduced
relative to wild-type controls. Similarly, in subcutaneous
sponge implants FGF-2-induced angiogenesis was also
impaired. However, another report has suggested that
CLEC14A may not serve as a viable antivascular target;
this study demonstrated that although implanted
tumour growth of LLC and B16F10 melanoma was
markedly impaired in CLEC14A knockout mice in com-
parison to wild-type littermates, tumour bearing
CLEC14A knockout mice died earlier [204]. These dele-
terious effects were attributed to reduced pericyte cover-
age and CLEC14A-deficient vessels displaying increased
permeability. Furthermore, this study revealed that
CLEC14A deficiency led to increased lung metastasis
burden when B16F10 cells were injected intravenously
or into the foot pad.
There are conflicting results regarding vessel sprout-
ing from aortic ring assays from CLEC14A KO mice.
Noy et al. described reduced sprouting in these CLEC14A-
deficient mice, but Lee et al. described increased sprout-
ing in aortic ring assays in comparison to control
[203,204]. The reasons for these described conflicting
roles for CLEC14A in angiogenesis have not been eluci-
dated. It is possible that discrepancies are due to differ-
ences in methodology of these assays or dissimilarities in
background strains of these CLEC14A KOmice.
The requirement for CLEC14A in various in vitro
angiogenesis assays were reported by two independent
groups utilising siRNA-mediated knockdown of
CLEC14A [189,196]. Based on these knockdown
experiments, the ability of HUVEC to form tubes and
close wounded monolayers in scratch assays was com-
promised. In addition, involvement of CLEC14A in
sprouting angiogenesis was demonstrated by siRNA
knockdown of CLEC14A in HUVEC which led to
marked reduction in sprout formation based on spher-
oid assays, CLEC14A deficient cells were also less
likely to be found as tip cells in these sprouts [203].
Ectopic expression of CLEC14A in cells that do not
normally express it, results in the formation of filopo-
dia-like protrusions [189]. Altogether these findings
implicate CLEC14A in filopodia formation, a vital
step in sprouting angiogenesis.
The CLEC14A CTLD has been implicated in cell–
cell adhesion interactions, since CLEC14A overex-
pressing HEK293F cells have the ability to initiate pre-
liminary cell–cell aggregates, which can be abolished
following incubation with CTLD-specific CLEC14A
antibodies [205]. These antibodies were reactive against
both human and mouse CLEC14A forms and could
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downregulate CLEC14A levels on the surface of
HUVEC, posing a potential for internalisation of anti-
bodies, and possible utilisation as ADCs carrying a
cytotoxic payload. Finally, these antibodies could
reduce HUVEC cell migration and tube formation
based on in vitro assays. Further studies optimised the
solubility and stability of the CLEC14A CTLD-target-
ing antibodies and showed that they could block
angiogenesis in mouse models utilising Matrigel plugs
injected with recombinant VEGF or human tumour
cells [206]. Collectively, these results suggest that the
CTLD of CLEC14A has functional roles in angiogene-
sis.
CLEC14A interaction partners
CLEC14A has been described as a component of
HUVEC ECM which binds to the ECM glycoprotein
MMRN2 [177]. Like CLEC14A, MMRN2 protein was
upregulated with tumour progression of two different
spontaneous mouse cancer models, highlighting impor-
tance of this interaction and potential as therapeutic
tumour vascular targets [177]. The CLEC14A–
MMRN2 interaction could be blocked by a mono-
clonal antibody specific for CLEC14A, and when
administered intraperitoneally retarded growth of sub-
cutaneously implanted LLC in mice [203]. This interac-
tion was dependent upon a predicted long-loop region
encompassing residues 97–108 within the CLEC14A
CTLD [101]. The CLEC14A-MMRN2 interaction
could also be targeted using a minimal peptide frag-
ment derived from MMRN2. This peptide reduced
endothelial tube formation and also decreased tumour
growth when expressed by LLC cells in vivo [101].
The CLEC14A CTLD also has the capacity to bind
other ligands including the heat shock protein 70 kDa
1A (HSP70-1A) which increased HUVEC adhesion,
aggregation and ERK phosphorylation [207]. This
finding may rationalise the cell aggregation effects
observed in HEK293F cells overexpressing CLEC14A,
with HSP70-1A forming oligomeric complexes and cre-
ating a bridge between CLEC14A expressed on differ-
ent cells. This binding phenomenon was dependent on
amino acids 43–69 of the CLEC14A CTLD [207],
which based on its predicted structure encompasses an
alpha helical region that is distal to the MMRN2
binding site. However, at present, it is unclear whether
HSP70-1A and MMRN2 are mutually exclusive bind-
ing events or if they compete with each other [101].
The same group previously discovered that HSP70-1A
could serve as a potent proangiogenic factor [208]. The
active HSP70-1A binding region of CLEC14A fused to
an Fc tag was used to create a novel peptibody which
could inhibit HSP70-1A–stimulated tubule formation
of HUVEC in vitro [207]. In the same study, stimula-
tion of HUVEC with HSP70-1A increased ERK phos-
phorylation, and this effect was reduced when
incubating with CLEC14A CTLD-Fc fusion proteins.
This suggests that CLEC14A may have signalling
roles, although the authors did not probe whether
HSP70-1A–mediated ERK phosphorylation was
blocked with knockdown of CLEC14A.
The intracellular domain of CLEC14A reportedly
interacts with vascular endothelial growth factor recep-
tor-3 (VEGFR-3) [204]. There are currently no other
known interactors for the CLEC14A cytoplasmic
domain, although global phosphoproteomic analysis of
HUVEC has revealed the presence of five serine resi-
dues that can be phosphorylated, namely S437, S445,
S483 S487 and S488 [209,210]. The phosphorylated
S483 was also found in other proteomic analyses and
was described as being close to a predicted PDZ bind-
ing domain in the CLEC14A cytoplasmic domain
[177]. Since these residues are not conserved in mouse
CLEC14A the relevance of these post-translational
modifications will need to be determined experimen-
tally. A summary of the protein interactions of
CLEC14A are shown in Fig. 6.
HSP70-1A
CLEC14A
MMRN2
VEGFR3
RHBDL2
Adhesion
LymphangiogenesisAdhesion
Angiogenesis
Fig. 6. Schematic of CLEC14A protein with
ligand binding partners. CLEC14A CTLD
binds to MMRN2 and to HSP70-1A. The
whole ECD can be cleaved by RHBDL2.
There are currently no known direct
intracellular partners for CLEC14A.
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CLEC14A shedding
CLEC14A can be shed from the endothelial cell mem-
brane by the intramembrane serine protease RHBDL2
[211]. RHBDL2 cleaves at a site close to the transmem-
brane domain, liberating the intact ECD of CLEC14A
to regulate sprouting angiogenesis. The CLEC14A-ECD
can mediate antiangiogenic effects in vitro and in vivo
when utilised as an Fc-tagged recombinant protein.
Intriguingly, when used as a staining reagent the
CLEC14A-ECD-Fc fusion bound to sprouting endothe-
lial cells, predominantly tip cells. Therefore, one could
propose a scenario in which shedding of CLEC14A may
aid in regulation of sprouting angiogenesis. Such cleaved
CLEC14A predominantly by stalk cells in an angiogenic
sprout would then be able to bind to tip cells.
CTLD group 14 family summary
The CTLD group 14 family members all mediate
effects upon the vasculature and some share remark-
able similarities with respect to binding partners loca-
lised within the extracellular matrix. Further
similarities are also observed with respect to expression
patterns and regulation by predicted transcription fac-
tors. A summary of similarities and differences are dis-
played in Table 1.
Expression localisation of CTLD group
14 family members in vivo
To gain an in-depth understanding of gene expression
of all four CTLD group 14 family members in vivo we
used the recently described Tabula Muris database,
which consists of single-cell transcriptomic analyses of
over 100 000 cells derived from 20 different healthy
adult mouse organs and tissues from C57BL/6 strain
mice [212]. This allowed graphical representation of
gene expression by use of t-SNE plots and revealed that
thrombomodulin is mainly expressed in endothelium,
epithelium and mesenchymal cell types, as well as some
myeloid, pro-B cell and bladder cells (Fig. 7). CD248 is
restricted mainly to mesenchymal cells, fibroblasts, peri-
cytes and bladder cells, and importantly there was a lack
of expression of CD248 in endothelial cells from multi-
ple organs. CD93 showed mainly endothelial, as well as
myeloid, pro-B cell and haematopoietic progenitor cell
expression, but a lack of expression in neurons. Finally,
CLEC14A exhibited the most endothelial specific
expression of the four family members but also localised
in bladder cells and leucocytes from the thymus. Bladder
cells described here include mesenchymal cell types. The
endothelial expression of CTLD group 14 family
members was then investigated further, t-SNE plots of
all endothelial cells from different organs as well as peri-
cytes from brain were created, showing that thrombo-
modulin is expressed in mostly all endothelial cell types,
CD248 is not expressed in endothelial cells (but is
expressed in pericytes) and CD93 and CLEC14A are
expressed to a varied degree in most endothelial cells
(Fig. 8A). As CD93 and CLEC14A share the ligand
MMRN2, they are both expressed by endothelium,
share similar endothelial phenotypes and have been sug-
gested previously to compensate for lack of the other,
we investigated whether endothelial cells in certain
organs displayed differential expression of each gene.
This revealed that CD93 is expressed higher than
CLEC14A in a majority of organs except kidney (no sig-
nificant difference) and liver, lung and pancreas
endothelium, where CLEC14A is expressed significantly
higher (Fig. 8B). Interestingly, there appeared to be a
subset of endothelial cells within the lung that do not
express CD93 but do express CLEC14A, t-SNE plots
solely of lung endothelium showed that there was a clus-
tering of these cells suggesting an unknown endothelial
subtype that does not express CD93 in mouse lung
(Fig. 8C). The Tabula Muris database provides novel
interesting insights into expression patterns, at least at
the gene expression level, in an adult healthy mouse,
although this is not an exhaustive list of all mouse cell
types that express these genes as only 20 major organs
and tissues were analysed. Similar studies analysing sin-
gle-cell gene expression of mice in different disease states
such as cancer or inflammation would be an extremely
valuable resource.
Considerations and perspectives
Similarities between CTLD group 14 family
members
All CTLD group 14 family members comprise six
canonical cysteines in the CTLD that are predicted to
form disulfide bonds and support the CTLD scaffold.
They also encompass two noncanonical cysteines
located within the predicted long-loop regions which
due to their close proximity may also form disulfide
links. Interestingly, such noncanonical cysteines within
the long-loop region are found only in three other
CTLD families; group 8 containing layilin and chon-
drolectin, groups 11 and 12. Disulfide bond formation
within this long loop appears to be essential for the
interaction of CLEC14A and CD93 with MMRN2.
Upon point mutation of these long-loop cysteines, the
CLEC14A CTLD folds correctly as it is recognised by
conformation-specific monoclonal antibodies, but
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completely diminishes its binding capability with
MMRN2 [101]. It is possible that the corresponding
cysteines in CD248 and thrombomodulin are similarly
important for CTLD-mediated recognition events and
constructs containing point mutations of these residues
could represent invaluable tools in determining func-
tional relevance of the CTLD within this family.
Thrombomodulin and CD93 are both anchored to
the actin cytoskeleton by associating with ERM adap-
ter proteins; thrombomodulin to ezrin and CD93 to
moesin. The thrombomodulin–ezrin interaction was
initially described in epithelial cells and this is not sur-
prising given that ezrin in this cell type is the highest
expressed ERM protein. In contrast in endothelial
cells, moesin is the most abundantly expressed ERM
protein [213]. Due to the high sequence homology
between ezrin and moesin (~ 75% sequence identity)
[214], it is tempting to speculate that thrombomodulin
also interacts with moesin in the endothelium. How-
ever, the ability of thrombomodulin to bind to ezrin
or moesin within endothelial cells is yet to be assessed.
Likewise, CD93 may be able to bind to multiple ERM
adapter proteins as is the case for CD44 binding to
ezrin, radixin and moesin [215]. Both thrombomodulin
and CD93 interactions with ERM adapter proteins are
dependent upon positively charged residues within the
cytoplasmic tail, which are absent in the corresponding
regions of CD248 and CLEC14A. This motif com-
prises of RKK in thrombomodulin and RKR in
CD93. Strikingly, the RKE motif in CLEC14A could
potentially abolish binding to ERM proteins due to
repulsion effects attributable to the negatively charged
glutamic acid side chain. Nevertheless, there is a dis-
tinct possibility that the intracellular domain of
CLEC14A makes direct or indirect contacts with the
cytoskeleton, due to its proposed roles in filopodia for-
mation and cell migration. Also, the corresponding
region in the CD248 intracellular domain consists of
the NKR motif, and it is unclear whether the non-
charged asparagine residue can compensate for binding
to ERM adapter proteins. Finally, a related point to
consider is that in both CD248 and CLEC14A, the
three-amino acid motif is preceded by a proline residue
which may cause rigidity and/or conformational alter-
ations that could affect interactions with ERM adapter
proteins.
Evidence for CLEC14A along with thrombomodulin
acting as potential cell adhesion molecules is observed
following overexpression of each protein and leads to
induced cell aggregation. Such effects are dependent
upon the CTLD of each protein [80,196,205]. HUVEC
plated on immobilised fragments of MMRN2 are suffi-
cient to allow adherence of HUVEC in cell binding
assays; however, at present, it is unclear whether
CLEC14A, CD93 or both mediate this adhesive func-
tion [101]. Similarly, when CD248 is overexpressed in
CHO cells, this enables them to bind to fibronectin
and Matrigel in cell adhesion assays [98].
CLEC14A and CD93 both bind MMRN2 as does
CD248, this to our knowledge is the first example of an
endothelial protein binding to an extracellular matrix
protein which in turn interacts with a pericyte-expressed
protein of the same family. This raises an interesting
question of how MMRN2 has evolved to bind two dis-
tinct CTLD group 14 family members in nonoverlap-
ping regions of the same molecule. This binding event
may have roles in already proposed CD248-dependent
vascular regression caused by pericytes [87]. With regard
to CLEC14A expression and MMRN2 interaction, this
may flag areas of the newly formed vasculature that is
experiencing low blood flow and low shear stress. Upon
binding to MMRN2 through CD248, pericytes could
then selectively cause vascular regression through
unknown mechanisms. Interestingly, pericyte coverage
of endothelium is reduced in the brain, retina and mela-
noma tumour vasculature of CLEC14A knockout mice
[204]. However, no defects were reported in pericyte
coverage of vessels in models of gliomas between CD93
knockout and wild-type mice [156]. This suggests that
CLEC14A may have more predominant roles in peri-
cyte attachment, or there could be differences in the
requirement of CLEC14A or CD93 in pericyte attach-
ment in different tissues.
MMRN2 has been shown to be a substrate for
MMP9, although it is unclear whether the subsequent
cleaved fragments can still bind to members of the
CTLD group 14 family and clearly warrants further
investigation [216]. Intriguingly, as mentioned previ-
ously, CD248 overexpression results in upregulation of
MMP9 posing a scenario in which MMRN2 could be
processed by MMP9 potentially regulating CD248–
MMRN2 binding. Alternatively, CD248-mediated
upregulation of MMP9 may allow cleavage of MMRN2
and detachment of the endothelial–pericyte interaction.
The EGF repeats and mucin-like regions of both
CD93 and thrombomodulin have been reported to
have proangiogenic effects. In the case of thrombo-
modulin, this mitogenic ability was abolished if the
CTLD was present on the soluble protein (i.e. includ-
ing the CTLD, sushi and EGF repeats), although it is
unclear whether this also applies for CD93. Neverthe-
less, one could speculate a scenario where differential
proteolytic cleavage of such proteins results in diverse
outcomes upon the endothelium and other cell types,
allowing fine tuning of cellular events. As discussed
previously, there is evidence that the CTLD of
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thrombomodulin can be shed from the full-length
molecule or from the cleaved ECD. Additionally, there
is likely a second cleavage event in the CLEC14A
ECD generating a fragment smaller than the full-
length ECD which encompasses the CTLD [211]. Mul-
tiple proteolytic cleavage events may be true for other
CTLD group 14 family members.
Potential roles in immunosuppression
Angiogenesis and immunosuppression are two tightly
regulated processes that often occur in unison. They
have been described as parallel processes especially in
the context of tumour angiogenesis and tumour
immunosuppression [217]. Many proangiogenic proteins
also mediate immunosuppressive effects upon the vascu-
lature as well as immune cells directly [218]. Here we
describe some examples of CTLD group 14 family mem-
bers that elicit immunosuppressive roles. For example,
expression of CD248 on na€ıve T-cells correlated with
decreased cell proliferation. In this setting, CD248 bind-
ing to its ligands that are upregulated in tumour angio-
genesis (i.e. MMRN2 or fibronectin etc.) may inhibit T-
cell proliferation. Similarly, thrombomodulin expression
on the vasculature or perhaps in soluble form can medi-
ate immunosuppressive functions upon binding GPR15
on T-cells as well as a whole host of other anti-inflam-
matory roles as described above. Although high expres-
sion of thrombomodulin has been reported by multiple
groups in diverse cancer indications, whether thrombo-
modulin can actually elicit an immunosuppressive func-
tion in the context of cancer remains to be elucidated
and the finding that low thrombomodulin leads to
improved prognosis seems to contradict this theory.
CD93 has also been described to trigger anti-inflamma-
tory events, such as limiting leucocyte migration in peri-
tonitis [170]. Other members of the CTLD group 14
family may invoke broader effects upon distinct compo-
nents of the immune system, and potentially contribute
to immunosuppression especially in the context of
tumours evading the immune system.
Potential use as therapeutic targets
So far clinical trials targeting CD248 have proved to
be very disappointing, and such agents may only be
effective in certain tumour types or may need to be
combined with other therapeutics for optimal clinical
benefit. However, CD248 targeting antibodies still
have promise as therapies for inflammatory or fibrotic
diseases where CD248 has a pathological role.
CLEC14A as a therapeutic target of the tumour vas-
culature has been investigated by many different pre-
clinical strategies using antibodies as well as fragments
of its known ligands and even chimeric antigen recep-
tor T-cells [219,220]. Since it is well established that
CLEC14A is expressed on vessels that experience low
shear stress and aberrant blood flow, it is conceivable
that only nonfunctional tumour vessels will be targeted
by such agents. This could prove beneficial as vascular
normalisation effects would likely take place, lowering
hypoxia, which could lead to better accumulation and
delivery of other drugs used in combination such as
chemotherapy. Additionally, such CLEC14A targeting
could be combined with immunotherapies which rely
on infiltration of effector immune cells into the tumour
mass, where functional and more ‘normal’ vasculature
would likely be advantageous [109].
In studies investigating the use of CLEC14A CTLD
specific antibodies, Kim et al. tested a human colorec-
tal cancer cell line HCT116 as well as a bevacizumab-
resistant version of this line. Both cell lines showed sig-
nificant reductions in in vivo angiogenesis following
treatment with CLEC14A antibodies when these cells
were embedded in Matrigel and injected subcuta-
neously [206]. This suggests a possible use for targeting
of CLEC14A in patients that have acquired resistance
to VEGF blockade. More importantly these findings
suggest that although targeting of CLEC14A can
reduce VEGF-dependent angiogenesis in various mod-
els, it may also ablate angiogenesis induced by VEGF-
independent pathways. However, the authors did not
assess the efficacy of these antibodies in targeting this
resistant cell line in tumour xenograft studies; there-
fore, the tangible benefit of CLEC14A targeting in
tumour types resistant to VEGF blockade is yet to be
fully established.
Dual targeting of CLEC14A and CD93 was
achieved by use of a MMRN2 fragment that contained
the CTLD-binding region (amino acid residues 495–
674 in human and 495–678 in mouse) fused to an Fc
tag [101]. This resulted in a decrease in syngeneic
Fig. 7. Expression of CTLD group 14 family members in mouse tissues. The Tabula Muris database was used to determine which mouse
cell types expressed each CTLD group 14 family gene from data acquired through fluorescence activated cell sorting and single-cell gene
expression analysis. The t-SNE plot at the top displays annotations of each cell type and shows a legend of colours corresponding to which
organ or tissue type that cell was from. The lower t-SNE plots display in which cell types each family member was expressed (purple), ln
(1 + CPM) is the natural logarithm of counts per million + 1.
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tumour growth in vivo and disruptions in angiogenesis
in vitro. Blocking CLEC14A and CD93 in this manner
will likely inhibit endothelial cells binding to endoge-
nous MMRN2 and may even interrupt the fibrogenesis
of fibronectin, as has been described with genetic abla-
tion of CD93 [167]. Furthermore, such targeting strate-
gies may destabilise the binding of CD248 expressing
pericytes to the tumour vasculature, although whether
this affects pericyte coverage remains to be investi-
gated. There is scepticism in the field in terms of
whether such pericyte targeting approaches provide
meaningful clinical benefit [221]. The use of such dual-
targeting approaches negates the ability of one protein
compensating the loss of the other. However, it is
important to note that this dual-targeting MMRN2
fragment Fc fusion protein was expressed directly in
the tumour microenvironment by genetically engi-
neered tumour cells. With less restricted expression of
the targeting fragment, we cannot rule out the possibil-
ity that this agent could display off target effects by
binding to other CD93 expressing cell types such as
monocytes or B-cells.
The likelihood of CTLD group 14 family members
serving as viable targets in cancer therapy will ultimately
depend on the expression profile of these proteins, which
if not tumour or tumour vasculature specific could
result in toxicity-related issues in patients. In this regard,
a seminal paper investigating targeting the tumour
endothelial marker and immunomodulatory molecule
CD276 (also referred to as B7-H3) described that the
most important determining factor for avoiding toxicity
is in fact level of expression [222,223]. Indeed, even
though CD276 displays a widespread expression pattern
in mouse and human tissues, the fact that it is so highly
expressed by tumour cells and the associated tumour
vasculature, resulted in ADCs against CD276 only hav-
ing substantial effects upon the tumour microenviron-
ment. In light of this data, experiments that determine
levels of target protein expression will likely become
paramount. Relatedly, low-affinity, high avidity thera-
peutic agents could be used against targets that are
highly expressed on tumour-associated tissue but still
expressed lowly on normal tissue; in this way, agents
would preferentially bind to highly expressing cell types.
This approach was demonstrated with low-affinity, high
avidity HER-2/CD3-binding bispecific agents that redi-
rect T-cells towards breast cancer cells [224]. These
high-avidity bispecific antibodies induced negligible
effects on in vivo tumour models expressing low levels of
HER-2 but successfully eradicated high-expressing
tumour lines, suggesting that normal tissues expressing
HER-2 at low levels may be avoided and toxicity min-
imised.
As mentioned previously, the cleavage of the CTLD
group 14 family members may negatively impact antibody
targeting therapies, as the soluble forms may sequester the
antibodies in the blood rendering them incapable of bind-
ing to the cell surface receptors. However, this issue will
likely be addressed in preclinical models and presumably
be overcome in phase I dose escalation studies of CTLD
group 14 family targeted agents.
High priority areas of future research
There are many unanswered questions relating to the
physiological and pathological functions of this family
of molecules, especially for CD248, CD93 and
CLEC14A. In particular, information on intracellular
signalling events is currently lacking.
It is currently unknown whether CLEC14A and
CD93 share other extracellular binding partners as is
the case for MMRN2. Likewise, other CTLD group
14 members may share additional binding proteins as
has been shown for HSP70-1 binding both CLEC14A
and thrombomodulin [25,207]. The region of human
CLEC14A CTLD that engages HSP70-1A exhibits
25.9% sequence identity to thrombomodulin, 29.6%
identity to CD93 and 33.3% to CD248; however, the
domain important for the thrombomodulin-HSP70-1
interaction has not yet been defined. Clearly further
binding experiments to extensively characterise interac-
tions between other CTLD group 14 family members
and newly described ligands will need to be conducted.
It is uncertain whether CLEC14A and CD93 com-
pete for binding with MMRN2 or whether they have
independent or similar roles. Also, the signalling
Fig. 8. Endothelial expression of CTLD group 14 family members in mouse tissues. (A) The Tabula Muris database was used to create t-
SNE plots of all endothelial cells from different organs as well as brain pericytes. The t-SNE plot at the top left displays a legend of colours
corresponding to which organ or tissue type that cell was from. Expression of each CTLD group 14 family member within these cell types
are displayed as t-SNE plots. (B) Single-cell sequencing data analysed as fragments per kilobase million was used to compare CD93 and
CLEC14A expression in different endothelial cells from different organs. Wilcoxon statistical test was used to compare ****P ≤ 0.0001
Aorta ECs n = 262, Brain nonmyeloid EC n = 1250, Diaphragm EC n = 154, Fat EC n = 1180, Heart EC n = 2274, Heart endocardial cell
n = 350, Kidney EC n = 80, Limb Muscle EC n = 258, Liver EC n = 392, Lung EC n = 1476, Mammary gland EC n = 98, Pancreas EC
n = 98, Trachea EC n = 66. (C) t-SNE plots of lung endothelium alone were created which revealed the presence of a cluster of cells
expressing low levels of CD93 when compared with all other lung endothelial cells but similar levels of CLEC14A (grey ellipse).
3320 The FEBS Journal 286 (2019) 3299–3332 ª 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
CTLD group 14 family K. A. Khan et al.
Brain Non−Myeloid pericyte
Brain Non−Myeloid endothelial cell
Fat endothelial cell
Heart endocardial cell
Heart endothelial cell
Kidney endothelial cell
Limb Muscle endothelial cell
Liver endothelial cell of sinusoid
Lung endothelial cell
Mammary Gland endothelial cell
Pancreas endothelial cell
Trachea endothelial cell
−20
0
20
40
tS
N
E
 2
0.0
2.5
5.0
7.5
log
0
2
4
6
log
**** **** **** ******** **** ********** ****ns ********
CD93
CLEC14A
THBD CD248
CD93 CLEC14A
Ao
rta
 EC
Br
ain
 no
n-
my
elo
id 
EC
Dia
ph
rag
m 
EC
Fa
t E
C
He
art
 EC
He
art
 en
do
ca
rdi
al 
    
    
    
ce
ll
0.5
0.4
0.3
0.2
0.1
0
FP
KM
Kid
ne
y E
C
Lim
b M
us
cle
EC     
 Li
ve
r E
C 
of 
he
pa
tic
 si
nu
so
id
Lu
ng
 EC
Ma
mm
ary
 
gla
nd
 EC
Pa
nc
rea
s E
C
Tra
ch
ea
 EC
−20
0
20
40
tS
N
E
 2
tSNE 1
−25 0 25 50
tSNE 1
tS
N
E
 2
−25 0 25 50
tSNE 1
−20
0
20
40
−25 0 25 50
0.0
2.5
5.0
7.5
log
0.0
2.5
5.0
7.5
log
−20
−10
0
10
20
−20 0 20
tSNE 1
tS
N
E 
2
−20
−10
0
10
20
tS
N
E 
2
0.0
2.5
5.0
7.5
CD93 CLEC14A
0.0
2.5
5.0
7.5
loglog
−20
0
20
40
tS
N
E
 2
−20
0
20
40
tS
N
E
 2
−25 0 25 50
tSNE 1
−25 0 25 50
tSNE 1
−20 0 20
tSNE 1
A
B
C
Cell type
3321The FEBS Journal 286 (2019) 3299–3332 ª 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
K. A. Khan et al. CTLD group 14 family
outcomes following MMRN2 binding to CLEC14A,
CD93 or CD248 are not fully established. CLEC14A
and CD93 have been postulated to have redundant
roles in zebrafish angiogenesis but not vasculogenesis
[225]. Simultaneous knockout of both CLEC14A and
CD93 led to more severe defects in intersegmental ves-
sel formation compared with single-gene knockouts,
now reported by two different groups [195]. VE-cad-
herin expression was absent in vessels that lacked
CLEC14A and CD93, suggesting abnormalities in
endothelial cell–cell adhesion, when VE-cadherin was
replaced this rescued the detrimental phenotype.
Knockdown of CD93 has also been shown to reduce
VE-cadherin levels in HUVEC [156], although pheno-
typic outcomes following double knockdown of both
CLEC14A and CD93 have not yet been reported in
mammalian cell types. Currently there are no data on
whether CLEC14A and CD93 display redundancy in
mammals, and a double KO mouse would begin to
address this important question.
Finally, as CLEC14A and CD93 have been
described as proteins highly expressed in the tumour
vasculature, with roles in angiogenesis, it remains to
be investigated whether these molecules are also
expressed and have roles in other routes in which a
tumour can acquire a blood supply. Two such mecha-
nisms involve (a) vessel co-option, whereby tumour
cells hijack the existing vasculature in highly vascu-
larised organs such as the lung, liver and brain [226],
or (b) vascular mimicry, where tumour cells can exhi-
bit endothelial-like properties and form functional ves-
sel like structures [227].
Concluding remarks
The CTLD group 14 is a family of molecules with
diverse roles in the vasculature, inflammation as well
as tumour progression. The increasing interest in these
molecules including elucidation of their normal biology
as well as their potential as therapeutic targets in can-
cer will likely continue to be explored in the future.
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